Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer
Randomized Control Study of Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer Patients
Sponsor: Japan Breast Cancer Research Network
A PHASE2 clinical study on Breast Neoplasms, this trial is completed. The trial is conducted by Japan Breast Cancer Research Network and has accumulated 7 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Apr 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Japan Breast Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .